Prot #CYTB323A12101: Phase I, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL

Project: Research project

Project Details

StatusActive
Effective start/end date2/1/2110/31/23

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CYTB323A12101)